干细胞之家 - 中国干细胞行业门户第一站

 

 

搜索
干细胞之家 - 中国干细胞行业门户第一站 干细胞之家论坛 干细胞行业新闻 自体iPS免疫排斥?Cells derived from iPSC can be immu ...
朗日生物

免疫细胞治疗专区

欢迎关注干细胞微信公众号

  
查看: 34293|回复: 0
go

自体iPS免疫排斥?Cells derived from iPSC can be immunogenic — Yes or No? [复制链接]

Rank: 3Rank: 3

积分
903 
威望
903  
包包
2427  

优秀会员 金话筒

楼主
发表于 2013-9-6 08:38 |显示全部帖子 |倒序浏览 |打印
Cells derived from iPSC can be immunogenic — Yes or No?& }5 F- s# d) i6 |2 g; b1 d5 j6 p1 ?
Cao J, Li X, Lu X, Zhang C, Yu H, Zhao T.! ^0 K8 \/ b6 W& H% |  C
State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China.0 d" J/ G' s$ I
Abstract
3 G0 D  N$ J$ G7 C! C- MThe induced pluripotent stem cells (iPSCs), derived by ectopic expression of reprogramming factors in somatic cells, can potentially provide unlimited autologous cells for regenerative medicine. In theory, the autologous cells derived from patient iPSCs should be immune tolerant by the host without any immune rejections. However, our recent studies have found that even syngeneic iPSC-derived cells can be immunogenic in syngeneic hosts by using a teratoma transplantation model (Zhao et al., 2011). Recently two research groups differentiated the iPSCs into different germ layers or cells, transplanted those cells to the syngeneic hosts, and evaluated the immunogenicity of those cells. Both of the two studies support our conclusions that some certain but not all tissues derived from iPSCs can be immunogenic, although they claimed either “negligible” or “lack of” immunogenicity in iPSC derivatives (Araki et al., 2013; Guha et al., 2013). To test the immunogenicity of clinically valuable cells differentiated from human iPSCs are emergently required for translation of iPSC technology to clinics.
* X$ V6 I1 I2 g, \+ Z, j
5 R* I6 Y. V: u原文地址:http://link.springer.com/article/10.1007%2Fs13238-013-3909-9) J# ?! [8 ?. U4 H2 V/ X& s
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册
验证问答 换一个

Archiver|干细胞之家 ( 吉ICP备2021004615号-3 )

GMT+8, 2025-5-17 07:47

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.